donation
To request Mental Health
Services or to access Mental
Health Crisis Services Call:
1-800-375-4357

Medical Disorders
Resources
Basic InformationLookupsLatest News
Obesity Could Raise Odds for 'Long-Haul' COVID SymptomsSmokers, Obese People Need Major Heart Interventions Earlier in LifeOld Age No Bar to Successful Heart Transplant, Study FindsCOVID Antibody Treatment Is Safe, Effective in Transplant PatientsExpiration Dates on Johnson & Johnson COVID Vaccine ExtendedWill People Really Need a Yearly COVID Booster Vaccine?America Is Losing the War Against DiabetesGene Editing Technique Corrects Sickle Cell Disease in MiceCOVID Vaccines Appear Safe for People With IBDNew Treatment Fights Rare Cases of Vaccine-Linked Blood ClotsWoman Dies From Dengue Fever Acquired in FloridaWhy a COVID Diagnosis Could Cost You Way More Money in 2021Vaccinations More Urgent as Variant That Crippled India Shows Up in the U.S.Think You Can Skip That Annual Physical?  Think AgainReal-World Study Shows Power of Pfizer, Moderna Vaccines to Prevent COVIDDeath Rates Are Rising Across Rural AmericaWhat Diet Is Most Likely to Help Ease Crohn's Disease?'Breakthrough' COVID Infections May Be Common in Vaccinated Transplant PatientsPeople of Color Have Twice the Risk of Dying After Brain Injury, Study FindsStudy Pinpoints Cancer Patients at Highest Risk From COVIDMany Existing Drugs Could Be Potent COVID Fighters: StudyAntibiotics Won't Help Fight Lung-Scarring Disease IDF: StudyNew Disabilities Plague Half of COVID Survivors After Hospital DischargeDeclining Vaccination Rates Threaten Biden's July 4 GoalYour Doctor Appointments Might Look Different Post-PandemicPrior COVID Infection May Shield You From Another for at Least 10 MonthsTeens: You Got Your COVID Vaccine, What Now?White House Lists Countries Getting First Batch of Extra COVID VaccinesStrokes Hitting COVID Patients Are More Severe: StudyAverage COVID Hospital Bill for U.S. Seniors Nearly $22,000Deep Brain Stimulation Therapy May Help Parkinson's Patients Long TermNIH Starts Trial Assessing 'Mix & Match' COVID Vaccine ApproachAllergy Treatment Crucial If Your Child Has AsthmaScientists Discover Rare Form of ALS That Can Strike KidsGlobal Warming to Blame for 1 in 3 Heat-Related Deaths WorldwideBlood Sugar Tests Using Sweat, Not Blood? They Could Be on the WayU.S. Set to Send Millions of COVID Vaccines to Countries in NeedAs Teen, He Made News Opposing Anti-Vax Mom. Now, He's Urging COVID Shots for YouthSmog Might Damage Your Sense of SmellU.S. Blood Supply Is Safe From Coronavirus, Study FindsAmericans' Lung Health: The Poor Suffer MostLosing Weight Can Beat Diabetes and Also Help the HeartIs It COVID-19 or Seasonal Allergies?Many Americans Confused About Sunscreens: PollAnother Study Finds Routine Vaccines Safe for Kids, AdultsDon't Delay Lung Cancer Surgery, Study SuggestsPoll Finds Herd Immunity in U.S. Possible by SummerDebunking Myths That Have Some Parents Resisting COVID Vaccines for TeensExperimental Treatment Offers New Hope Against LupusMany Pre-Surgery Tests Are Useless, So Why Are Hospitals Still Using Them?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

About 1 in 7 Who Get Pfizer Vaccine Will Have Any 'Systemic' Side Effect: Study

HealthDay News
by Steven Reinberg
Updated: Apr 28th 2021

new article illustration

WEDNESDAY, April 28, 2021 (HealthDay News) -- Only 13.5% of people will suffer systemic side effects after getting Pfizer's coronavirus vaccine, a new study finds.

These systemic symptoms include headache, fatigue and tenderness. Most side effects are mild and peak in the day after being vaccinated, and they only last for one to two days, according to the findings.

The analysis was done by researchers from King's College London using data on more than 627,000 people. They found fewer side effects with both the Pfizer and AstraZeneca vaccines than was seen in clinical trials. AstraZeneca's vaccine has not been approved for use in the United States.

Study author Dr. Cristina Menni said, "Our results support the aftereffects safety of both vaccines with fewer side effects in the general population than reported in the Pfizer and AstraZeneca experimental trials and should help allay safety concerns of people willing to get vaccinated."

The investigators also found lower infection rates in the 12 to 21 days after the first dose of the Pfizer (58%) and AstraZeneca (39%) vaccines, compared with people who weren't vaccinated. The drop in infection rates at least 21 days after the first dose of Pfizer was 69%, while it was 60% for AstraZeneca.

This large analysis looked at side effects including headache, fatigue, chills and shivering, diarrhea, fever, joint pain, muscle pain and nausea. They also looked at side effects where the injection took place in the arm, including pain at the injection site, swelling, tenderness, redness, itch, warmth and swollen armpit glands.

Other findings include:

  • Nearly 14% had side effects after the first Pfizer dose, 22% after the second Pfizer dose and 34% after the first AstraZeneca dose. The most common side effect was headache. Eight percent of people reported suffered headaches after the first Pfizer dose and 13% after the second Pfizer dose.
  • About a quarter (23%) of those who had the first dose of the AstraZeneca vaccine reported a headache.
  • The second most common side effect was fatigue. Eight percent and 14% of participants reported fatigue after the first and second dose of Pfizer vaccine, while 21% reported fatigue after their first dose of AstraZeneca vaccine. The most common local side effect was tenderness: 57% and 51% after the first and second dose of Pfizer vaccine, and 49% after the first dose of AstraZeneca vaccine.
  • Side effects were more common among people under age 55 and women.
  • People who had COVID-19 were three times more likely to have side effects after doses of the Pfizer vaccine than those who didn't have COVID-19. For those who had the AstraZeneca vaccine, that effect was nearly two times greater.
  • People who had COVID-19 were also more likely to have local side effects regardless of which vaccine they got.

"The data should reassure many people that in the real world, aftereffects of the vaccine are usually mild and short-lived, especially in the over 50s who are most at risk of the infection," said lead scientist Tim Spector, a professor of genetic epidemiology at King's College London.

"The results also show up to 70% protection after three weeks following a single dose, which is fantastic news for the country, especially as more people have now had their second jabs," Spector said in a college news release.

The report was published April 27 in The Lancet Infectious Diseases journal.

More information

For more on COVID-19 vaccines, head to the U.S. Centers for Disease Control and Prevention.

SOURCE: King's College London, news release, April 27, 2021